Payoneer Global Inc vs Viatris Inc — how do they compare? Payoneer Global Inc trades at $7.14 (market cap $2.43B), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: Viatris Inc is far larger — about 8.2× Payoneer Global Inc's market cap, and Viatris Inc pays a 2.75% dividend while Payoneer Global Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Payoneer Global Inc for 61 Days and Viatris Inc for 57 Days on average.
| PAYO | VTRS | |
|---|---|---|
Market Cap | $2.43B | $20.03B |
Volume | 1,342,701 | 14,109,977 |
Sector | Technology | Health |
52-Week High | $7.18 | $18.27 |
52-Week Low | $4.27 | $9.74 |
Typical Hold Time | 61 Days | 57 Days |
Enterprise Value | $2.17B | $32.15B |
Dividend Yield | — | 2.75% |
Signals from Pluang's Aura AI — not financial advice
Payoneer Global (PAYO) trades at $7.16 with mixed technical signals showing a bullish moving average trend but neutral oscillators. The company reported Q2 2026 earnings of $0.02 per share, missing estimates of $0.05761, though revenue grew 10% year-over-year excluding interest. Recent developments include the renewal of its partnership with Etsy through 2029 and expansion of its India innovation hub.
The pending acquisition by Nuvei creates uncertainty, but analyst sentiment remains positive with 60% buy ratings. Key risks include integration challenges from the acquisition and competitive pressures in the fintech sector, while opportunities lie in continued B2B growth and international expansion.
Viatris (VTRS) trades at $17.44, down 0.29% on the day, with a bullish technical outlook supported by moving averages and oversold RSI levels. The company has beaten earnings estimates for three consecutive quarters, though it faces profitability challenges with negative net margins. Recent positive developments include FDA approval for WAKIX in Japan and consistent dividend payments, while analyst consensus leans toward a buy rating with a $22.17 price target representing 27% upside potential.
The stock presents a value opportunity with reasonable P/S and P/B ratios, but investors must weigh strong cash generation against persistent profitability issues. Key catalysts include continued earnings beats and pipeline progress, while risks involve margin pressure and high debt levels. The current valuation disconnect between technical strength and fundamental challenges creates a balanced risk-reward profile for patient investors.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Payoneer Global Inc is the world's go-to partner for digital commerce, everywhere. The company started as a cross-border payments platform that empowers businesses, online sellers, and freelancers. The platform allows the users to get paid in multiple currencies, bill global clients, and sell on marketplaces worldwide.
Read more on PAYO →Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →